Sponsor:
Vanderbilt University Medical Center
Code:
NCT05812755
Conditions
Endothelial Dysfunction
Vascular Diseases
Kidney Injury
Brain Disease
Vascular Inflammation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Vericiguat
Placebo
Brief summary:
Conditions
Endothelial Dysfunction
Vascular Diseases
Kidney Injury
Brain Disease
Vascular Inflammation
Study ID
NCT05812755
Start date
May 19, 2023
Status verified date
Aug, 2026
Completion date
Jul, 2029
Anticipated
Primary completion date
Jul, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
170 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Basic Science
Arms
active comparator: Vericiguat
placebo comparator: Placebo
Interventions
Vericiguat
Placebo
Primary outcome measure
Locations
Vanderbilt University Medical Center
Recruiting
Nashville, Tennessee, United States, 37204
Contacts
Sponsor
Vanderbilt University Medical Center
Last update posted
Aug 6, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Vanderbilt University Medical Center on 2026-08-06.